Literature DB >> 17244809

Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study.

Eiman M Mokaddas1, Noura A Al-Sweih1, Zia U Khan1.   

Abstract

Bloodstream infections due to Candida species are important complications in severely ill hospitalized patients. This study presents data on species distribution and antifungal susceptibility profiles of Candida bloodstream isolates obtained from Kuwait during a 10-year period. All the bloodstream isolates were identified to species level by the germ tube test and carbohydrate assimilation profile using the VITEK 2 yeast identification system. Using E-test strips for amphotericin B, fluconazole, 5-flucytosine and voriconazole, MICs were determined on RPMI agar supplemented with 2% glucose. The MIC breakpoints for resistance were based on Clinical and Laboratory Standards Institute criteria or those published by reference laboratories, and were as follows: amphotericin B, >1 microg ml-1; fluconazole, >or=64 microg ml-1; 5-flucytosine, >or=32 microg ml-1; and voriconazole, 4 microg ml-1. In all, 607 bloodstream yeast isolates were obtained over the past 10 years in Kuwait. Candida albicans was the predominant species (39.5%), followed by Candida parapsilosis (30.6%), Candida tropicalis (12.4%), Candida glabrata (5.6%) and Candida krusei (1.6%). All C. albicans, C. tropicalis and C. glabrata isolates were susceptible to amphotericin B. Of 186 isolates of C. parapsilosis tested, only four (2%) exhibited an MIC for amphotericin B of >1 microg ml-1. Resistance to fluconazole was observed in nine (3.8%) C. albicans isolates, two (5.8%) C. glabrata isolates and four (40%) C. krusei isolates. Resistance to 5-flucytosine was observed in two (0.8%) C. albicans isolates, seven (9.3%) C. tropicalis isolates, three (1.6%) C. parapsilosis isolates and all ten (100%) C. krusei isolates. All the isolates of C. albicans, C. tropicalis, C. parapsilosis, C. glabrata and C. krusei were susceptible to voriconazole, including those resistant to fluconazole. Although amphotericin B and fluconazole are widely used in clinical practice in Kuwait, resistance to these drugs remained low.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17244809     DOI: 10.1099/jmm.0.46817-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  30 in total

1.  Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Ana Alastruey-Izquierdo; Leticia Bernal-Martinez; Isabel Cuesta; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

2.  Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment?

Authors:  Habip Gedik; Funda Şimşek; Taner Yıldırmak; Arzu Kantürk; Deniz Arıca; Demet Aydın; Naciye Demirel; Osman Yokuş
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-02       Impact factor: 0.900

3.  The effect of antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida species induced biofilms.

Authors:  Nermin H Ibrahim; Nahla A Melake; Ali M Somily; Azza S Zakaria; Manal M Baddour; Amany Z Mahmoud
Journal:  Saudi Pharm J       Date:  2013-12-22       Impact factor: 4.330

Review 4.  Insights into Candida tropicalis nosocomial infections and virulence factors.

Authors:  M Negri; S Silva; M Henriques; R Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-30       Impact factor: 3.267

5.  Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.

Authors:  Dilek Yesim Metin; Suleyha Hilmioglu-Polat; Pinar Samlioglu; Biray Doganay-Oflazoglu; Ramazan Inci; Emel Tumbay
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

6.  Interlaboratory reproducibility of Etest amphotericin B and caspofungin yeast susceptibility testing and comparison with the CLSI method.

Authors:  S Ranque; L Lachaud; M Gari-Toussaint; A Michel-Nguyen; M Mallié; J Gaudart; S Bertout
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

7.  Prevalent drug resistance among oral yeasts from asymptomatic patients in Hainan, China.

Authors:  Jinyan Wu; Hong Guo; Guohui Yi; Limin Zhou; Xiaowen He; Xianxi Huang; Huamin Wang; Weiling Xue; Jianping Xu
Journal:  Mycopathologia       Date:  2014-05-10       Impact factor: 2.574

8.  Comparison Between Biofilm Production, Phospholipase and Haemolytic Activity of Different Species of Candida Isolated from Dental Caries Lesions in Children.

Authors:  J Udayalaxmi; Neetha Shenoy
Journal:  J Clin Diagn Res       Date:  2016-04-01

9.  Antifungal Activity of Cinnamon Oil and Olive Oil against Candida Spp. Isolated from Blood Stream Infections.

Authors:  Nidhi Goel; Hina Rohilla; Gajender Singh; Parul Punia
Journal:  J Clin Diagn Res       Date:  2016-08-01

10.  Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.

Authors:  Jin-Sol Lee; Jong Hee Shin; Kyungwon Lee; Mi-Na Kim; Bo-Moon Shin; Young Uh; Wee-Gyo Lee; Hye Soo Lee; Chulhun L Chang; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.